{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matched+placebo&page=31",
    "query": {
      "intervention": "matched placebo",
      "page": 31
    },
    "page_size": 10
  },
  "pagination": {
    "page": 31,
    "page_size": 10,
    "total_count": 7016,
    "total_pages": 702,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matched+placebo&page=32&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matched+placebo&page=30&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T21:05:50.446Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02442778",
      "title": "Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Agitation in Participants With Dementia of the Alzheimer's Type"
      ],
      "interventions": [
        {
          "name": "AVP-786-18",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "AVP-786-28",
          "type": "DRUG"
        },
        {
          "name": "AVP-786-42.63",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 522,
      "start_date": "2015-11-11",
      "completion_date": "2019-09-09",
      "has_results": true,
      "last_update_posted_date": "2022-09-09",
      "last_synced_at": "2026-10-21T21:05:50.446Z",
      "location_count": 79,
      "location_summary": "Chandler, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 55 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02442778"
    },
    {
      "nct_id": "NCT03657355",
      "title": "Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Recreational Drug Users"
      ],
      "interventions": [
        {
          "name": "ACT-541468",
          "type": "DRUG"
        },
        {
          "name": "Suvorexant",
          "type": "DRUG"
        },
        {
          "name": "Zolpidem",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Idorsia Pharmaceuticals Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 63,
      "start_date": "2018-09-07",
      "completion_date": "2019-08-08",
      "has_results": false,
      "last_update_posted_date": "2019-09-19",
      "last_synced_at": "2026-10-21T21:05:50.446Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03657355"
    },
    {
      "nct_id": "NCT07673887",
      "title": "A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastric Adenocarcinoma",
        "Gastroesophageal Junction (GEJ) Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "ASP2138",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Folinic acid",
          "type": "DRUG"
        },
        {
          "name": "5-FU",
          "type": "DRUG"
        },
        {
          "name": "Placebo for ASP2138",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 570,
      "start_date": "2026-07-28",
      "completion_date": "2031-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-21T21:05:50.446Z",
      "location_count": 1,
      "location_summary": "Saint Louis Park, Minnesota",
      "locations": [
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07673887"
    },
    {
      "nct_id": "NCT01163721",
      "title": "Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Ranolazine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 80,
      "start_date": "2010-06",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2013-09-23",
      "last_synced_at": "2026-10-21T21:05:50.446Z",
      "location_count": 9,
      "location_summary": "Escondido, California • Los Angeles, California • Miami, Florida + 6 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01163721"
    },
    {
      "nct_id": "NCT00789633",
      "title": "Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Masitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AB Science",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 353,
      "start_date": "2008-11-25",
      "completion_date": "2012-08-31",
      "has_results": false,
      "last_update_posted_date": "2018-12-17",
      "last_synced_at": "2026-10-21T21:05:50.446Z",
      "location_count": 12,
      "location_summary": "Norwich, Connecticut • Orlando, Florida • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Norwich",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Galesburg",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00789633"
    },
    {
      "nct_id": "NCT03262038",
      "title": "Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pruritus",
        "Nausea/Vomiting"
      ],
      "interventions": [
        {
          "name": "Ondansetron",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 46,
      "start_date": "2017-12-07",
      "completion_date": "2019-08-20",
      "has_results": true,
      "last_update_posted_date": "2021-01-19",
      "last_synced_at": "2026-10-21T21:05:50.446Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03262038"
    },
    {
      "nct_id": "NCT07830758",
      "title": "Resmetirom in Patients With MASH and HFpEF",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "MASH - Metabolic Dysfunction-Associated Steatohepatitis",
        "Heart Failure With Preserved Ejection Fraction (HFPEF)"
      ],
      "interventions": [
        {
          "name": "Resmetirom",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Madrigal Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2026-09",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-21T21:05:50.446Z",
      "location_count": 5,
      "location_summary": "Peoria, Arizona • Oxnard, California • Fort Myers, Florida + 2 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Riverview",
          "state": "Florida"
        },
        {
          "city": "University Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07830758"
    },
    {
      "nct_id": "NCT04688164",
      "title": "A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "REL-1017",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Relmada Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 227,
      "start_date": "2021-01-08",
      "completion_date": "2022-11-10",
      "has_results": true,
      "last_update_posted_date": "2024-08-27",
      "last_synced_at": "2026-10-21T21:05:50.446Z",
      "location_count": 11,
      "location_summary": "Miami, Florida • Miami Springs, Florida • Palm Bay, Florida + 8 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami Springs",
          "state": "Florida"
        },
        {
          "city": "Palm Bay",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04688164"
    },
    {
      "nct_id": "NCT04836806",
      "title": "Cetirizine and Famotidine for COVID-19",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Cetirizine and Famotidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-08",
      "completion_date": "2022-07",
      "has_results": false,
      "last_update_posted_date": "2021-08-20",
      "last_synced_at": "2026-10-21T21:05:50.446Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04836806"
    },
    {
      "nct_id": "NCT03659929",
      "title": "Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Amphetamine Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arbor Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 320,
      "start_date": "2018-09-18",
      "completion_date": "2019-04-12",
      "has_results": true,
      "last_update_posted_date": "2024-09-03",
      "last_synced_at": "2026-10-21T21:05:50.446Z",
      "location_count": 31,
      "location_summary": "Encino, California • Garden Grove, California • Newport Beach, California + 26 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Cromwell",
          "state": "Connecticut"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03659929"
    }
  ]
}